Suggested remit: To appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic kidney disease.
 
Status In progress
Process STA 2018
ID number 3866

Provisional Schedule

Committee meeting 14 October 2021
Expected publication 05 January 2022

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors AstraZeneca (dapagliflozin)
Others Department of Health and Social Care
Patient carer groups Kidney Care UK
Professional groups Primary Care Diabetes Society
  Renal Association
  Royal College of Physicians

Commentators

Comparator companies Accord (captopril, enalapril, eplerenone, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, telmisartan, trandolapril, valsartan) – confidentiality agreement not signed, not participating
  Aspire (eplerenone) – confidentiality agreement not signed, not participating
  AstraZeneca (lisinopril)
  Aurobindo pharma (candesartan, carvedilol, enalapril, fosinopril irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan) – confidentiality agreement not signed, not participating
  Boehringer Ingelheim (telmisartan)
  Bristol laboratories (lisinopril) – confidentiality agreement not signed, not participating
  Brown and Burk (irbesartan, lisinopril, losartan, ramipril) – confidentiality agreement not signed, not participating
  Consilient health (candesartan, eplerenone, irbesartan, losartan, perindopril, telmisartan) – confidentiality agreement not signed, not participating
  Daiichi Sankyo (olmesartan) – confidentiality agreement not signed, not participating
  Dexcel pharma (enalapril, losartan, valsartan) – confidentiality agreement not signed, not participating
  Glenmark pharma (olmesartan, perindopril, telmisartan) – confidentiality agreement not signed, not participating
  Lupin Healthcare (irbesartan) – confidentiality agreement not signed, not participating
  Martindale pharma (captopril) – confidentiality agreement not signed, not participating
  Novartis (valsartan)
  Organon (enalapril, losartan) – confidentiality agreement not signed, not participating
  Pfizer (quinapril) – confidentiality agreement not signed, not participating
  Sandoz (candesartan, losartan, ramipril, telmisartan) – confidentiality agreement not signed, not participating
  Sanofi (irbesartan, ramipril) – confidentiality agreement not signed, not participating
  Servier laboratories (perindopril) – confidentiality agreement not signed, not participating
  Takeda (azilsartan, candesartan) – confidentiality agreement not signed, not participating
  Ten pharma (captopril) – confidentiality agreement not signed, not participating
  Thame laboratories (captopril) – confidentiality agreement not signed, not participating
  Thornton & Ross (olmesartan) – confidentiality agreement not signed, not participating
  Tillomed laboratories (eplerenone, perindopril) – confidentiality agreement not signed, not participating
  Viatris. (candesartan, enalapril, eplerenone, eprosartan, fosinopril lisinopril, losartan, olmesartan, perindopril, trandolapril, valsartan) – confidentiality agreement not signed, not participating
  Zentiva (eplerenone, irbesartan, ramipril) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
30 March 2021 Invitation to participate
30 March 2021 In progress. Invitation to participate issued
03 February 2021 - 03 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance